Methods for selecting medications

Abstract

The invention provides computer assisted methods for selecting an antidepressant medication for a patient. The methods utilize a combination genotype comprising at least three genes to guide medication selection.

1 - 47 . (canceled) 
     
     
         48 . A method for treating a patient in need thereof with a psychotropic medication in a manner that reduces the patient's risk of hallucination in response to treatment with said psychotropic medication, the method comprising the steps of:
 (a) obtaining or having obtained a biological sample from said patient,   (b) performing or having performed a genotyping assay on a panel of at least three genes from said biological sample   (c) identifying said patient as being at increased risk of hallucination in response to treatment with said psychotropic medication if said patient is a poor metabolizer for said psychotropic medication; and   (d) administering to a patient identified as at increased risk of hallucination in response to a psychotropic medication, a medication selected from the group of medications that are acceptable to use with said genotype and medications that may be used with caution with said genotype.   
     
     
         49 . The method of  claim 48 , wherein said at least three genes are CYP2D6, CYP1A2 and CYP2C19. 
     
     
         50 . The method of  claim 49 , wherein said panel further comprises at least one additional gene selected from the group of genes comprising CYP3A4, CYP1A1, a dopamine transporter gene, a serotine receptor gene, dopamine receptor D1, dopamine receptor D2, dopamine receptor D3, dopamine receptor D4, dopamine receptor D5, dopamine receptor D6, serotonin receptor 1A, serotonin receptor 1B, serotonin receptor 1D, serotonin receptor 2A, serotonin receptor 2C, catechoyl-O-methyl transferase gene, CYP1B1, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2E1, CYP3A5, a tryptophan hydroxylase gene, DAT1, and TPH gene. 
     
     
         51 . The method of  claim 49 , wherein said panel further comprises at least two additional genes selected from the group of genes comprising CYP3A4, CYP1A1, a dopamine transporter gene, a serotine receptor gene, dopamine receptor D1, dopamine receptor D2, dopamine receptor D3, dopamine receptor D4, dopamine receptor D5, dopamine receptor D6, serotonin receptor 1A, serotonin receptor 1B, serotonin receptor 1D, serotonin receptor 2A, serotonin receptor 2C, catechoyl-O-methyl transferase gene, CYP1B1, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2E1, CYP3A5, 5HTTR, a tryptophan hydroxylase gene, DAT1, and TPH gene. 
     
     
         52 . The method of  claim 48 , wherein said psychotropic medication is selected from the group of psychotropic medications comprising an antipsychotic agent, an antianxiety-sedative agent, a mood-stabilizing agent, an anti-depressant, clonazepam, trazodone, lamotrigine, oxycarbazepine, aripiprazole, bupropion, mirtazapine, fluvoxamine, sertraline, amitriptyline, nortriptyline, venlafaxine, paroxetine, citalopram, escitalopram, and imipramine. 
     
     
         53 . The method of  claim 49 , wherein said patient in need of a psychotropic medication is in need of an anti-anxiety sedative agent and wherein said panel further comprises at least one additional gene selected from the group of genes comprising serotonin receptor 1A, serotonin receptor 1B, serotonin receptor 1D, serotonin receptor 2A, serotonin receptor 2C, 5HTTR, and serotonin transporter gene. 
     
     
         54 . The method of  claim 49 , wherein said patient in need of a psychotropic medication is in need of a mood stabilizing agent and wherein said panel further comprises at least one additional gene selected from the group of genes comprising 5HTTR, HTR2A, serotonin transporter, and CYP3A4. 
     
     
         55 . The method of  claim 49 , wherein said patient in need of a psychotropic medication is in need of an antipsychotic agent and wherein said panel further comprises a dopamine transporter gene. 
     
     
         56 . The method of  claim 49 , wherein said patient in need of a psychotropic medication is in need of an anti-depressant and wherein said panel further comprises at least one additional gene selected from the group comprising a serotonin transporter gene, a serotonin receptor gene, a serotonin receptor 2A gene, CYP3A4, 5HTTR, and HTR2A. 
     
     
         57 . The method of  claim 48 , wherein said psychotropic medication is selected from the group of psychotropic medications comprising an antipsychotic agent, an antianxiety-sedative agent, a mood-stabilizing agent an anti-depressant, clonazepam, trazodone, lamotrigine, oxycarbazepine, aripiprazole, bupropion, mirtazapine, fluvoxamine, sertraline, amitriptyline, nortriptyline, venlafaxine, paroxetine, citalopram, escitalopram, and imipramine. 
     
     
         58 . The method of  claim 57 , wherein the step of administering to said patient a medication comprises administering a medication selected from the group comprising clonazepam, trazodone, lamotrigine, oxycarbazepine, and pariprazole.